未找到相关数据
A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19
被引：34
作者：
Goss, G. D.
Lorimer, I.
Tsao, M. S.
O'Callaghan, C. J.
Ding, K.
Masters, G. A.
Roberts, P.
Jett, J. R.
Edelman, M. J.
Shepherd, F. A.
机构：
[1] Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada
[2] Ottawa Hosp, Res Inst, Ottawa, ON, Canada
[3] Princess Margaret Hosp, Univ Hlth Network, Toronto, ON M4X 1K9, Canada
[4] NCIC Clin Trials Grp, Kingston, ON, Canada
[5] Med Oncol Hematol Consultants PA, Newark, DE USA
[6] Univ Calif Davis, Sacramento, CA 95817 USA
[7] Naval Med Ctr, Portsmouth, VA USA
[8] Mayo Clin, Rochester, MN USA
[9] Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[10] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada
关键词：
D O I：
10.1200/jco.2010.28.18_suppl.lba7005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA7005
引用
收藏
页数：1
相关论文